Adma Biologics reported $3.42M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Adma Biologics USD 3.42M 1.32M Jun/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Omeros USD 4.05M 5.16M Sep/2024
Takeda JPY 63.38B 466M Sep/2026